Intranasal dexmedetomidine in artificial abortion-vacuum aspiration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005654

Enrollment

Unknown

Registered

2014-12-11

Start date

2014-02-18

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedation in artificial abortion

Interventions

propofol:non

SP:propofol+sulfentanil

dexmedetomidine:intranasal dexmedetomidine

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 18-35 years old, pregnancy of 8-10 weeks, ASA I-II, who were undergoing elective artificial abortion-vacuum aspiration in the clinic of gynaecology and obstetrics of Dalian medical university.

Exclusion criteria

Exclusion criteria: Patients with known allergy or regular use of dexmedetomidine, opoids and propofol, sedatives, and history of abortion or labor, impaired liver or renal function, alcohol consumption in excess 28 units per week, known psychological disorder, asthma, heart disease, BMI more than 24kg/m2, sleep apnea syndrome and patient refusal were excluded

Design outcomes

Primary

Measure	Time frame
dosage of propofol;	—

Countries

China

Contacts

Public ContactJie Liu

liujaye@hotmail.com+86 15941173650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 9, 2026